NR 566 Midterm Exam - Advanced Pharmacology for Care of the Family 2026/2027 Curriculum
NR 566 Midterm Examination
Advanced Pharmacology for Care of the Family
Complete Questions and Verified Answers - 2026/2027 Curriculum
Aligned with Chamberlain University NR566 Advanced Practice Nursing Standards
Total Questions Exam Sections Cognitive Levels Curriculum Year
120 8 25% Recall / 55% Application / 20% Analysis 2026/2027
Section 1: Advanced Pharmacokinetics and Pharmacodynamics (Q1-Q20)
Q1: A nurse practitioner is reviewing the first-pass effect with a nursing student. Which statement by the student
demonstrates correct understanding?
A. Intravenous drugs undergo significant first-pass metabolism in the liver
B. First-pass metabolism occurs after systemic circulation distributes the drug to tissues
C. Oral drugs with high first-pass metabolism may require higher doses to achieve therapeutic effect
[CORRECT]
D. First-pass effect only applies to drugs administered via the sublingual route
Correct Answer: C
Rationale: The first-pass effect refers to the pre-systemic metabolism of orally administered drugs by the liver before reaching systemic
circulation. Drugs with high first-pass extraction (e.g., propranolol, morphine, nitroglycerin) lose a significant portion of their
bioavailability, often requiring larger oral doses. IV drugs bypass first-pass metabolism entirely, achieving 100% bioavailability.
Q2: A patient with hepatic cirrhosis is prescribed a highly protein-bound medication (98%). Which pharmacokinetic
alteration is most concerning in this patient?
A. Increased volume of distribution leading to delayed onset of action
B. Reduced renal clearance of the protein-bound fraction
C. Enhanced first-pass metabolism due to portal hypertension
D. Decreased protein binding leading to increased free drug concentration and toxicity risk [CORRECT]
Correct Answer: D
Rationale: Hepatic cirrhosis reduces albumin synthesis, decreasing the number of available protein-binding sites. For highly
protein-bound drugs (e.g., warfarin, phenytoin), this leads to a greater proportion of free (active) drug in circulation, potentially
causing toxicity at standard doses. The volume of distribution of the free drug increases, but the primary clinical concern is the elevated
free drug concentration.
Q3: Which CYP450 enzyme is responsible for metabolizing the largest number of commonly prescribed medications?
A. CYP2C9
B. CYP2C19
C. CYP1A2
Chamberlain University - NR566 Advanced Practice Nursing Page 1
,NR 566 Midterm Exam - Advanced Pharmacology for Care of the Family 2026/2027 Curriculum
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 is the most abundant CYP450 enzyme in the liver and intestines and is responsible for metabolizing approximately
50% of all clinically used drugs. It is critically important for drug interactions because many inhibitors (ketoconazole, erythromycin,
grapefruit juice) and inducers (rifampin, carbamazepine, St. John's Wort) affect this enzyme.
Q4: A patient taking warfarin for atrial fibrillation is started on rifampin for tuberculosis. What is the expected clinical
outcome?
A. Decreased INR due to CYP450 enzyme induction [CORRECT]
B. Increased INR due to CYP450 enzyme inhibition
C. No change in INR because warfarin is renally cleared
D. Increased risk of bleeding due to protein-binding displacement
Correct Answer: A
Rationale: Rifampin is a potent CYP450 enzyme inducer that increases the metabolism of warfarin (primarily a CYP2C9 substrate),
leading to decreased warfarin levels and a subtherapeutic INR. This reduces anticoagulant efficacy and increases thromboembolic risk.
The NP should anticipate needing a higher warfarin dose and monitor INR closely when rifampin is initiated.
Q5: A nurse practitioner is counseling a patient about drug-food interactions. The patient drinks grapefruit juice daily.
Which medication interaction is most clinically significant?
A. Increased metabolism of sertraline due to CYP2C19 induction
B. Enhanced renal excretion of metformin
C. Decreased metabolism of simvastatin due to intestinal CYP3A4 inhibition [CORRECT]
D. Reduced absorption of levothyroxine due to gastric pH changes
Correct Answer: C
Rationale: Grapefruit juice inhibits intestinal CYP3A4 enzymes and OATP transporters, reducing the first-pass metabolism of CYP3A4
substrates like simvastatin, atorvastatin, and certain calcium channel blockers. This can lead to significantly elevated drug levels and
increased risk of toxicity, particularly rhabdomyolysis with high-dose simvastatin.
Q6: A patient is prescribed a medication with a half-life of 12 hours. Approximately how long will it take to reach
steady-state concentration?
A. 12 hours
B. 24 hours
C. 120 hours
D. 48 to 60 hours [CORRECT]
Correct Answer: D
Rationale: Steady state is achieved after approximately 4 to 5 half-lives of a drug. For a drug with a 12-hour half-life, steady state is
reached in 48 to 60 hours (4 x 12 = 48 hours). This principle is critical for determining when to evaluate drug efficacy and adjust
doses, as drug levels accumulate predictably during repeated dosing.
Q7: Aripiprazole is classified as a partial agonist at the D2 receptor. What is the clinical significance of this
pharmacodynamic property?
A. It produces maximal dopamine receptor stimulation regardless of endogenous dopamine levels
B. It requires CYP2D6 activation to become pharmacologically active
C. It has no affinity for serotonin receptors, limiting its therapeutic use
D. It acts as an antagonist when dopamine levels are high and as a weak agonist when dopamine is low
[CORRECT]
Correct Answer: D
Chamberlain University - NR566 Advanced Practice Nursing Page 2
,NR 566 Midterm Exam - Advanced Pharmacology for Care of the Family 2026/2027 Curriculum
Rationale: Aripiprazole is a third-generation antipsychotic with partial D2 agonist activity. In hyperdopaminergic states (e.g.,
psychosis), it competes with endogenous dopamine and acts as a functional antagonist. In hypodopaminergic states, it provides weak
agonist activity. This unique property reduces the risk of extrapyramidal side effects compared to full D2 antagonists.
Q8: A patient who is a CYP2D6 poor metabolizer is prescribed clopidogrel for coronary artery disease. What is the
most appropriate clinical action?
A. No change is needed; clopidogrel is not metabolized by CYP2D6
B. Add omeprazole to enhance clopidogrel absorption
C. Double the clopidogrel dose to compensate for reduced metabolism
D. Switch to prasugrel or ticagrelor due to impaired clopidogrel bioactivation [CORRECT]
Correct Answer: D
Rationale: Clopidogrel is a prodrug that requires bioactivation by CYP2C19 (not CYP2D6). However, CYP2C19 poor metabolizers
have significantly reduced conversion of clopidogrel to its active metabolite, leading to decreased antiplatelet effect and increased
cardiovascular events. Prasugrel and ticagrelor do not require CYP2C19 activation and are preferred alternatives for patients with
reduced CYP2C19 function.
Q9: A nurse practitioner is reviewing the volume of distribution (Vd) for several medications. A drug with a very large
Vd (e.g., 5 L/kg) would most likely be:
A. Highly protein-bound and confined to the vascular compartment
B. Hydrophilic and primarily excreted unchanged by the kidneys
C. Lipophilic and extensively distributed to extravascular tissues [CORRECT]
D. Too large to cross the blood-brain barrier
Correct Answer: C
Rationale: A large volume of distribution indicates extensive tissue distribution beyond the plasma compartment. Lipophilic drugs (e.g.,
digoxin, amiodarone, verapamil) readily cross cell membranes and accumulate in fat, muscle, and organs, resulting in Vd values much
greater than total body water. Highly protein-bound or hydrophilic drugs tend to have smaller Vd values.
Q10: A patient taking tramadol develops hyperthermia, agitation, diaphoresis, and tremors. The nurse practitioner
suspects serotonin syndrome. Which combination of medications is most likely responsible?
A. Tramadol and sertraline [CORRECT]
B. Tramadol and ibuprofen
C. Tramadol and metformin
D. Tramadol and lisinopril
Correct Answer: A
Rationale: Tramadol inhibits serotonin and norepinephrine reuptake. When combined with SSRIs/SNRIs (e.g., sertraline, fluoxetine,
venlafaxine), there is an increased risk of serotonin syndrome, a potentially life-threatening condition caused by excessive serotonergic
activity. Symptoms range from mild (diaphoresis, tremor) to severe (hyperthermia, seizures, coma).
Q11: Which of the following drugs has a narrow therapeutic index requiring therapeutic drug monitoring?
A. Amoxicillin
B. Lisinopril
C. Lithium [CORRECT]
D. Metformin
Correct Answer: C
Rationale: Lithium has a narrow therapeutic index (therapeutic level 0.6-1.2 mEq/L; toxicity >1.5 mEq/L). Small changes in dose or
factors affecting renal clearance (dehydration, NSAIDs, ACE inhibitors, thiazide diuretics) can rapidly lead to toxicity. Other narrow
TI drugs include digoxin, warfarin, vancomycin, and phenytoin. Therapeutic drug monitoring is essential for safe use.
Chamberlain University - NR566 Advanced Practice Nursing Page 3
, NR 566 Midterm Exam - Advanced Pharmacology for Care of the Family 2026/2027 Curriculum
Q12: A nurse practitioner is reviewing pharmacogenomic testing results. Which genetic marker is associated with a
life-threatening hypersensitivity reaction to abacavir?
A. CYP2D6 *4 allele
B. TPMT deficiency
C. HLA-B*5701 [CORRECT]
D. VKORC1 polymorphism
Correct Answer: C
Rationale: HLA-B*5701 is a human leukocyte antigen allele strongly associated with a hypersensitivity reaction to abacavir, an
antiretroviral medication. The reaction can be severe and potentially fatal (fever, rash, organ involvement). FDA guidelines
recommend HLA-B*5701 screening before initiating abacavir therapy, and the drug is contraindicated in patients who test positive.
Q13: Which medication follows zero-order kinetics at therapeutic doses, meaning a constant amount (rather than a
constant proportion) is eliminated per unit time?
A. Metoprolol
B. Amoxicillin
C. Phenytoin [CORRECT]
D. Prednisone
Correct Answer: C
Rationale: Phenytoin follows Michaelis-Menten (saturable or zero-order) kinetics at therapeutic concentrations because its hepatic
metabolizing enzymes become saturated. Small dose increases can produce disproportionately large increases in serum concentration,
leading to toxicity. This is why phenytoin dosing requires careful monitoring and dose adjustments should be small (25-30 mg
increments).
Q14: A patient with known VKORC1 polymorphism is being initiated on warfarin. How does this genetic variation
affect warfarin dosing?
A. The patient will likely require a higher initial warfarin dose due to increased sensitivity
B. VKORC1 polymorphisms have no effect on warfarin dosing requirements
C. The patient will likely require a lower initial warfarin dose due to increased sensitivity [CORRECT]
D. The patient will need twice-daily dosing instead of once-daily
Correct Answer: C
Rationale: VKORC1 polymorphisms affect the sensitivity of the vitamin K epoxide reductase enzyme complex (warfarin's target).
Patients with certain VKORC1 variants (e.g., -1639G>A) have increased sensitivity to warfarin and require lower doses to achieve
therapeutic anticoagulation. Pharmacogenomic-guided dosing algorithms incorporating both VKORC1 and CYP2C9 genotypes improve
time to therapeutic INR.
Q15: A nurse practitioner is administering a medication intravenously. What is the expected bioavailability of this
route?
A. 75-80%
B. 50-60%
C. 100% [CORRECT]
D. 90-95%
Correct Answer: C
Rationale: Intravenous administration bypasses all barriers to absorption (no first-pass effect, no GI degradation, no absorption
variability), resulting in 100% bioavailability. This route provides the most predictable and complete drug delivery to the systemic
circulation. Oral bioavailability varies widely depending on the drug's physicochemical properties and first-pass metabolism.
Q16: A patient taking cimetidine develops toxicity from another medication. What is the mechanism of this drug
interaction?
Chamberlain University - NR566 Advanced Practice Nursing Page 4
NR 566 Midterm Examination
Advanced Pharmacology for Care of the Family
Complete Questions and Verified Answers - 2026/2027 Curriculum
Aligned with Chamberlain University NR566 Advanced Practice Nursing Standards
Total Questions Exam Sections Cognitive Levels Curriculum Year
120 8 25% Recall / 55% Application / 20% Analysis 2026/2027
Section 1: Advanced Pharmacokinetics and Pharmacodynamics (Q1-Q20)
Q1: A nurse practitioner is reviewing the first-pass effect with a nursing student. Which statement by the student
demonstrates correct understanding?
A. Intravenous drugs undergo significant first-pass metabolism in the liver
B. First-pass metabolism occurs after systemic circulation distributes the drug to tissues
C. Oral drugs with high first-pass metabolism may require higher doses to achieve therapeutic effect
[CORRECT]
D. First-pass effect only applies to drugs administered via the sublingual route
Correct Answer: C
Rationale: The first-pass effect refers to the pre-systemic metabolism of orally administered drugs by the liver before reaching systemic
circulation. Drugs with high first-pass extraction (e.g., propranolol, morphine, nitroglycerin) lose a significant portion of their
bioavailability, often requiring larger oral doses. IV drugs bypass first-pass metabolism entirely, achieving 100% bioavailability.
Q2: A patient with hepatic cirrhosis is prescribed a highly protein-bound medication (98%). Which pharmacokinetic
alteration is most concerning in this patient?
A. Increased volume of distribution leading to delayed onset of action
B. Reduced renal clearance of the protein-bound fraction
C. Enhanced first-pass metabolism due to portal hypertension
D. Decreased protein binding leading to increased free drug concentration and toxicity risk [CORRECT]
Correct Answer: D
Rationale: Hepatic cirrhosis reduces albumin synthesis, decreasing the number of available protein-binding sites. For highly
protein-bound drugs (e.g., warfarin, phenytoin), this leads to a greater proportion of free (active) drug in circulation, potentially
causing toxicity at standard doses. The volume of distribution of the free drug increases, but the primary clinical concern is the elevated
free drug concentration.
Q3: Which CYP450 enzyme is responsible for metabolizing the largest number of commonly prescribed medications?
A. CYP2C9
B. CYP2C19
C. CYP1A2
Chamberlain University - NR566 Advanced Practice Nursing Page 1
,NR 566 Midterm Exam - Advanced Pharmacology for Care of the Family 2026/2027 Curriculum
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 is the most abundant CYP450 enzyme in the liver and intestines and is responsible for metabolizing approximately
50% of all clinically used drugs. It is critically important for drug interactions because many inhibitors (ketoconazole, erythromycin,
grapefruit juice) and inducers (rifampin, carbamazepine, St. John's Wort) affect this enzyme.
Q4: A patient taking warfarin for atrial fibrillation is started on rifampin for tuberculosis. What is the expected clinical
outcome?
A. Decreased INR due to CYP450 enzyme induction [CORRECT]
B. Increased INR due to CYP450 enzyme inhibition
C. No change in INR because warfarin is renally cleared
D. Increased risk of bleeding due to protein-binding displacement
Correct Answer: A
Rationale: Rifampin is a potent CYP450 enzyme inducer that increases the metabolism of warfarin (primarily a CYP2C9 substrate),
leading to decreased warfarin levels and a subtherapeutic INR. This reduces anticoagulant efficacy and increases thromboembolic risk.
The NP should anticipate needing a higher warfarin dose and monitor INR closely when rifampin is initiated.
Q5: A nurse practitioner is counseling a patient about drug-food interactions. The patient drinks grapefruit juice daily.
Which medication interaction is most clinically significant?
A. Increased metabolism of sertraline due to CYP2C19 induction
B. Enhanced renal excretion of metformin
C. Decreased metabolism of simvastatin due to intestinal CYP3A4 inhibition [CORRECT]
D. Reduced absorption of levothyroxine due to gastric pH changes
Correct Answer: C
Rationale: Grapefruit juice inhibits intestinal CYP3A4 enzymes and OATP transporters, reducing the first-pass metabolism of CYP3A4
substrates like simvastatin, atorvastatin, and certain calcium channel blockers. This can lead to significantly elevated drug levels and
increased risk of toxicity, particularly rhabdomyolysis with high-dose simvastatin.
Q6: A patient is prescribed a medication with a half-life of 12 hours. Approximately how long will it take to reach
steady-state concentration?
A. 12 hours
B. 24 hours
C. 120 hours
D. 48 to 60 hours [CORRECT]
Correct Answer: D
Rationale: Steady state is achieved after approximately 4 to 5 half-lives of a drug. For a drug with a 12-hour half-life, steady state is
reached in 48 to 60 hours (4 x 12 = 48 hours). This principle is critical for determining when to evaluate drug efficacy and adjust
doses, as drug levels accumulate predictably during repeated dosing.
Q7: Aripiprazole is classified as a partial agonist at the D2 receptor. What is the clinical significance of this
pharmacodynamic property?
A. It produces maximal dopamine receptor stimulation regardless of endogenous dopamine levels
B. It requires CYP2D6 activation to become pharmacologically active
C. It has no affinity for serotonin receptors, limiting its therapeutic use
D. It acts as an antagonist when dopamine levels are high and as a weak agonist when dopamine is low
[CORRECT]
Correct Answer: D
Chamberlain University - NR566 Advanced Practice Nursing Page 2
,NR 566 Midterm Exam - Advanced Pharmacology for Care of the Family 2026/2027 Curriculum
Rationale: Aripiprazole is a third-generation antipsychotic with partial D2 agonist activity. In hyperdopaminergic states (e.g.,
psychosis), it competes with endogenous dopamine and acts as a functional antagonist. In hypodopaminergic states, it provides weak
agonist activity. This unique property reduces the risk of extrapyramidal side effects compared to full D2 antagonists.
Q8: A patient who is a CYP2D6 poor metabolizer is prescribed clopidogrel for coronary artery disease. What is the
most appropriate clinical action?
A. No change is needed; clopidogrel is not metabolized by CYP2D6
B. Add omeprazole to enhance clopidogrel absorption
C. Double the clopidogrel dose to compensate for reduced metabolism
D. Switch to prasugrel or ticagrelor due to impaired clopidogrel bioactivation [CORRECT]
Correct Answer: D
Rationale: Clopidogrel is a prodrug that requires bioactivation by CYP2C19 (not CYP2D6). However, CYP2C19 poor metabolizers
have significantly reduced conversion of clopidogrel to its active metabolite, leading to decreased antiplatelet effect and increased
cardiovascular events. Prasugrel and ticagrelor do not require CYP2C19 activation and are preferred alternatives for patients with
reduced CYP2C19 function.
Q9: A nurse practitioner is reviewing the volume of distribution (Vd) for several medications. A drug with a very large
Vd (e.g., 5 L/kg) would most likely be:
A. Highly protein-bound and confined to the vascular compartment
B. Hydrophilic and primarily excreted unchanged by the kidneys
C. Lipophilic and extensively distributed to extravascular tissues [CORRECT]
D. Too large to cross the blood-brain barrier
Correct Answer: C
Rationale: A large volume of distribution indicates extensive tissue distribution beyond the plasma compartment. Lipophilic drugs (e.g.,
digoxin, amiodarone, verapamil) readily cross cell membranes and accumulate in fat, muscle, and organs, resulting in Vd values much
greater than total body water. Highly protein-bound or hydrophilic drugs tend to have smaller Vd values.
Q10: A patient taking tramadol develops hyperthermia, agitation, diaphoresis, and tremors. The nurse practitioner
suspects serotonin syndrome. Which combination of medications is most likely responsible?
A. Tramadol and sertraline [CORRECT]
B. Tramadol and ibuprofen
C. Tramadol and metformin
D. Tramadol and lisinopril
Correct Answer: A
Rationale: Tramadol inhibits serotonin and norepinephrine reuptake. When combined with SSRIs/SNRIs (e.g., sertraline, fluoxetine,
venlafaxine), there is an increased risk of serotonin syndrome, a potentially life-threatening condition caused by excessive serotonergic
activity. Symptoms range from mild (diaphoresis, tremor) to severe (hyperthermia, seizures, coma).
Q11: Which of the following drugs has a narrow therapeutic index requiring therapeutic drug monitoring?
A. Amoxicillin
B. Lisinopril
C. Lithium [CORRECT]
D. Metformin
Correct Answer: C
Rationale: Lithium has a narrow therapeutic index (therapeutic level 0.6-1.2 mEq/L; toxicity >1.5 mEq/L). Small changes in dose or
factors affecting renal clearance (dehydration, NSAIDs, ACE inhibitors, thiazide diuretics) can rapidly lead to toxicity. Other narrow
TI drugs include digoxin, warfarin, vancomycin, and phenytoin. Therapeutic drug monitoring is essential for safe use.
Chamberlain University - NR566 Advanced Practice Nursing Page 3
, NR 566 Midterm Exam - Advanced Pharmacology for Care of the Family 2026/2027 Curriculum
Q12: A nurse practitioner is reviewing pharmacogenomic testing results. Which genetic marker is associated with a
life-threatening hypersensitivity reaction to abacavir?
A. CYP2D6 *4 allele
B. TPMT deficiency
C. HLA-B*5701 [CORRECT]
D. VKORC1 polymorphism
Correct Answer: C
Rationale: HLA-B*5701 is a human leukocyte antigen allele strongly associated with a hypersensitivity reaction to abacavir, an
antiretroviral medication. The reaction can be severe and potentially fatal (fever, rash, organ involvement). FDA guidelines
recommend HLA-B*5701 screening before initiating abacavir therapy, and the drug is contraindicated in patients who test positive.
Q13: Which medication follows zero-order kinetics at therapeutic doses, meaning a constant amount (rather than a
constant proportion) is eliminated per unit time?
A. Metoprolol
B. Amoxicillin
C. Phenytoin [CORRECT]
D. Prednisone
Correct Answer: C
Rationale: Phenytoin follows Michaelis-Menten (saturable or zero-order) kinetics at therapeutic concentrations because its hepatic
metabolizing enzymes become saturated. Small dose increases can produce disproportionately large increases in serum concentration,
leading to toxicity. This is why phenytoin dosing requires careful monitoring and dose adjustments should be small (25-30 mg
increments).
Q14: A patient with known VKORC1 polymorphism is being initiated on warfarin. How does this genetic variation
affect warfarin dosing?
A. The patient will likely require a higher initial warfarin dose due to increased sensitivity
B. VKORC1 polymorphisms have no effect on warfarin dosing requirements
C. The patient will likely require a lower initial warfarin dose due to increased sensitivity [CORRECT]
D. The patient will need twice-daily dosing instead of once-daily
Correct Answer: C
Rationale: VKORC1 polymorphisms affect the sensitivity of the vitamin K epoxide reductase enzyme complex (warfarin's target).
Patients with certain VKORC1 variants (e.g., -1639G>A) have increased sensitivity to warfarin and require lower doses to achieve
therapeutic anticoagulation. Pharmacogenomic-guided dosing algorithms incorporating both VKORC1 and CYP2C9 genotypes improve
time to therapeutic INR.
Q15: A nurse practitioner is administering a medication intravenously. What is the expected bioavailability of this
route?
A. 75-80%
B. 50-60%
C. 100% [CORRECT]
D. 90-95%
Correct Answer: C
Rationale: Intravenous administration bypasses all barriers to absorption (no first-pass effect, no GI degradation, no absorption
variability), resulting in 100% bioavailability. This route provides the most predictable and complete drug delivery to the systemic
circulation. Oral bioavailability varies widely depending on the drug's physicochemical properties and first-pass metabolism.
Q16: A patient taking cimetidine develops toxicity from another medication. What is the mechanism of this drug
interaction?
Chamberlain University - NR566 Advanced Practice Nursing Page 4
